To investigate the role of thromboxane A2 (TxA2) in murine lupus, we assessed the effects of the specific thromboxane receptor antagonist GR32191 on immune complex glomerulonephritis in MRL-lpr/lpr mice. Forty mg/kg/day GR32191 was given by twice daily subcutaneous injection for eight weeks beginning at 12 weeks of age. This dose completely blocked the renal vasoconstriction produced by the thromboxane agonist U46619. After eight weeks of treatment, both glomerular filtration rate (GFR) (8.9 ± 0.6 vs. 6.8 ± 1.1 ml/min/kg; P PAH) (37.4 ± 2.5 vs. 29.9 ± 3.3 ml/min/kg; P2 (TxB2) in urine (292 ± 37 vs. 747 ± 155 pg/24 hr; P 2 is an important mediator of renal dysfunction and injury in this murine model of lupus nephritis.
|Original language||English (US)|
|Number of pages||10|
|State||Published - Apr 1992|
ASJC Scopus subject areas